Compare · ONMD vs PPD
ONMD vs PPD
Side-by-side comparison of OneMedNet Corp (ONMD) and PPD, Inc. (PPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ONMD and PPD operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- PPD is the larger of the two at $16.64B, about 442.7x ONMD ($37.6M).
- ONMD has hit the wire 2 times in the past 4 weeks while PPD has been quiet.
- PPD has more recent analyst coverage (1 ratings vs 0 for ONMD).
- Company
- OneMedNet Corp
- PPD, Inc.
- Price
- $0.71+4.08%
- $47.29-0.07%
- Market cap
- $37.6M
- $16.64B
- 1M return
- -27.82%
- -
- 1Y return
- +86.35%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 0
- 1
PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Latest ONMD
- OneMedNet Surpasses 90 Million Patient Journeys and 270 Million Studies within its Network
- Director Kosasa Thomas bought $250,000 worth of shares (268,817 units at $0.93), increasing direct ownership by 2% to 16,930,144 units (SEC Form 4)
- SEC Form 424B3 filed by OneMedNet Corp
- SEC Form 10-Q filed by OneMedNet Corp
- Amendment: SEC Form 10-K/A filed by OneMedNet Corp
- Chief Medical Officer Yu Jeffrey was granted 219,429 shares and bought $750,000 worth of shares (903,614 units at $0.83), increasing direct ownership by 15% to 8,449,266 units (SEC Form 4)
- Director Kosasa Thomas bought $749,999 worth of shares (876,136 units at $0.86), increasing direct ownership by 6% to 16,661,327 units (SEC Form 4)
- OneMedNet Goes Live with 80 Million Patient Journeys and Billions of Records
- OneMedNet Corp filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data
Latest PPD
- InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
- Saama Appoints Scott Rogers as Company's Chief Financial Officer
- SEC Form 15-12B filed by PPD, Inc.
- SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)
- SEC Form SC 13G filed by PPD, Inc.
- SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)
- SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company
- SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company
- SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company